S
32.91
0.15 (0.46%)
| 前收盘价格 | 32.76 |
| 收盘价格 | 33.00 |
| 成交量 | 1,307,834 |
| 平均成交量 (3个月) | 1,172,303 |
| 市值 | 3,121,849,088 |
| 价格/销量 (P/S) | 13.14 |
| 股市价格/股市净资产 (P/B) | 13.05 |
| 52周波幅 | |
| 利润日期 | 5 May 2025 - 9 May 2025 |
| 稀释每股收益 (EPS TTM) | -2.55 |
| 总债务/股东权益 (D/E MRQ) | 20.22% |
| 流动比率 (MRQ) | 10.25 |
| 营业现金流 (OCF TTM) | -229.84 M |
| 杠杆自由现金流 (LFCF TTM) | -134.32 M |
| 资产报酬率 (ROA TTM) | -50.15% |
| 股东权益报酬率 (ROE TTM) | -106.71% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Scholar Rock Holding Corporatio | 看涨 | 看涨 |
AIStockmoo 评分
2.0
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 2.00 |
|
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 4.35% |
| 机构持股比例 | 118.63% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 50.00 (Jefferies, 51.93%) | 购买 |
| 中 | 45.00 (36.74%) | |
| 低 | 45.00 (Barclays, 36.74%) | 购买 |
| 45.00 (BMO Capital, 36.74%) | 购买 | |
| 平均值 | 46.67 (41.81%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 32.55 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Barclays | 17 Sep 2025 | 45.00 (36.74%) | 购买 | 31.67 |
| Jefferies | 21 Aug 2025 | 50.00 (51.93%) | 购买 | 34.59 |
| BMO Capital | 07 Aug 2025 | 45.00 (36.74%) | 购买 | 31.40 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合